NZ Immuno-Oncology Research Review Issue 10

In this issue:

5-year survival with nivolumab + ipilimumab in advanced melanoma
Pembrolizumab vs. ipilimumab in advanced melanoma
Pembrolizumab in relapsed/ refractory HL
Immune-related adverse events and prognosis in nivolumab-treated gastric cancer
T-DM1 ±pertuzumab vs. trastuzumab/taxane for HER2+ advanced breast cancer
Nivolumab beyond RECIST progression in head/neck squamous cell carcinoma
Nivolumab monotherapy in recurrent/metastatic cervical, vaginal or vulvar cancer
5-year OS with pembrolizumab for advanced NSCLC
4-year survival with nivolumab in previously treated advanced NSCLC
Pembrolizumab ± stereotactic body radiotherapy in advanced NSCLC
Pembrolizumab after locally ablative therapy for oligometastatic NSCLC
Neoadjuvant T-DM1 + pertuzumab in HER2+ breast cancer

Please login below to download this issue (PDF)